IT1253009B - Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini - Google Patents
Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vacciniInfo
- Publication number
- IT1253009B IT1253009B ITMI913513A ITMI913513A IT1253009B IT 1253009 B IT1253009 B IT 1253009B IT MI913513 A ITMI913513 A IT MI913513A IT MI913513 A ITMI913513 A IT MI913513A IT 1253009 B IT1253009 B IT 1253009B
- Authority
- IT
- Italy
- Prior art keywords
- toxin
- preparation
- ser
- arg
- vaccines
- Prior art date
Links
- 239000003053 toxin Substances 0.000 title abstract 3
- 231100000765 toxin Toxicity 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 108020004705 Codon Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108700012359 toxins Proteins 0.000 abstract 2
- 101100230463 Caenorhabditis elegans his-44 gene Proteins 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 241000607598 Vibrio Species 0.000 abstract 1
- 230000000688 enterotoxigenic effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000002703 mutagenesis Methods 0.000 abstract 1
- 231100000350 mutagenesis Toxicity 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Abstract
La presente invenzione si riferisce a tossoidi proteici immunogenici ottenuti per mutagenesi puntiforme del gene di Vibrio Cholerac codificante la Tossina Colerica (CT), o del gene della tossina LT prodotta dai ceppi enterotossigenici di Escherichia coli (ETEC), nei codoni relativi agli aminoacidi Leu-41, Ala-45, Val-53, Ser-63, Ala-72, Ser-75, Val-97, His-107 o Arg-210 singolarmente, o in combinazione con mutazioni a carico dei codoni relativi agli aminoacidi Arg-7, His-44, Arg-54, Ser-61, Glu-110, Glu-112 o Ser-114 ed al loro uso per la preparazione di vaccini utili per il trattamento di infezioni coleriche o diarrea rispettivamente.
Priority Applications (32)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI913513A IT1253009B (it) | 1991-12-31 | 1991-12-31 | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
DK98200534T DK0869181T3 (da) | 1991-12-31 | 1992-12-30 | Immunogene detoksificerede mutanter af choleratoksin og af LT-tolsin, fremstillingen deraf og anvendelsen deraf til fremstilling af vacciner |
AT98200534T ATE277183T1 (de) | 1991-12-31 | 1992-12-30 | Immunogene, nichtgiftige mutanten des choleratoxins und des toxins-lt, ihre herstellung und ihre verwendung zur herstellung von impfstoffen |
SG1996008033A SG48217A1 (en) | 1991-12-31 | 1992-12-30 | Immunogenic detoxified mutants of cholera toxin and of the toxin lt their preparation and their use for the preparation of vaccines |
DE69228563T DE69228563T2 (de) | 1991-12-31 | 1992-12-30 | Immunogene, nichtgiftige mutanten des choleratoxins und des toxins-lt, ihre herstellung und ihre verwendung zur herstellung von impfstoffen |
PCT/EP1992/003016 WO1993013202A1 (en) | 1991-12-31 | 1992-12-30 | Immunogenic detoxified mutants of cholera toxin and of the toxin lt, their preparation and their use for the preparation of vaccines |
DK04076971T DK1484404T3 (da) | 1991-12-31 | 1992-12-30 | Immunogene detoksificerede mutanter af choleratoksin og af toksinet LT, fremstilling deraf og anvendelse deraf til fremstilling af vacciner |
AU33476/93A AU3347693A (en) | 1991-12-31 | 1992-12-30 | Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines |
ES98200534T ES2227762T3 (es) | 1991-12-31 | 1992-12-30 | Mutantes destoxificados inmunogenos de toxina del colera y de la toxina lt,su preparacion y uso para la preparacion de vacunas. |
AT04076971T ATE346932T1 (de) | 1991-12-31 | 1992-12-30 | Immunogene, nichtgiftige mutanten des choleratoxins und des toxins-lt, ihre herstellung und ihre verwendung zur herstellung von impfstoffen |
AT93902138T ATE177145T1 (de) | 1991-12-31 | 1992-12-30 | Immunogene, nichtgiftige mutanten des choleratoxins und des toxins-lt, ihre herstellung und ihre verwendung zur herstellung von impfstoffen |
ES04076971T ES2277195T3 (es) | 1991-12-31 | 1992-12-30 | Mutantes destoxificados inmunogenos de toxina del coleray de la toxina lt, su preparacion y uso en la preparacion de vacunas. |
ES93902138T ES2127808T3 (es) | 1991-12-31 | 1992-12-30 | Mutantes destoxificados inmunogenos de la toxina del colera y de las toxinas termolabiles (lt), preparacion y utilizacion de los mismos para la preparacion de vacunas. |
DE69233417T DE69233417T2 (de) | 1991-12-31 | 1992-12-30 | Immunogene, nichtgiftige Mutanten des Choleratoxins und des Toxins-LT, ihre Herstellung und ihre Verwendung zur Herstellung von Impfstoffen |
CA002127091A CA2127091C (en) | 1991-12-31 | 1992-12-30 | Immunogenic detoxified mutants of cholera toxin and of the toxin lt, their preparation and their use for the preparation of vaccines |
EP98200534A EP0869181B1 (en) | 1991-12-31 | 1992-12-30 | Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines |
DE69233667T DE69233667T2 (de) | 1991-12-31 | 1992-12-30 | Immunogene, nichtgiftige Mutanten des Choleratoxins und des Toxins-LT, ihre Herstellung und ihre Verwendung zur Herstellung von Impfstoffen |
SG9901947A SG93200A1 (en) | 1991-12-31 | 1992-12-30 | Immunogenic detoxified mutants of cholera toxin and of the toxin lt, their preparation and their use for the preparation of vaccines |
EP93902138A EP0620850B1 (en) | 1991-12-31 | 1992-12-30 | Immunogenic detoxified mutants of cholera toxin and of the toxin lt, their preparation and their use for the preparation of vaccines |
PT04076971T PT1484404E (pt) | 1991-12-31 | 1992-12-30 | Mutantes imunogénicos destoxificados da toxina da cólera e das toxinas termolábeis (lt), preparação e utilização destes mutantes para a preparação das vacinas |
JP51144793A JP3394774B2 (ja) | 1991-12-31 | 1992-12-30 | コレラトキシンの免疫原性無毒化変異体およびトキシンltの免疫原性無毒化変異体,それらの調製,ならびにワクチンの調製のためのそれらの使用 |
EP04076971A EP1484404B1 (en) | 1991-12-31 | 1992-12-30 | Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines |
DK93902138T DK0620850T3 (da) | 1991-12-31 | 1992-12-30 | Immunogene detoksificerede mutanter af choleratoksin og af toksinet LT, deres fremstilling og deres anvendelse til fremstil |
MX9207685A MX9207685A (es) | 1991-12-31 | 1992-12-31 | Proteina inmunogenica destoxoficada, composicion para vacuna que la contiene y proceso para la formulacion de dicha vacuna. |
MYPI92002409A MY108154A (en) | 1991-12-31 | 1992-12-31 | Immunogenic detoxified mutants, of cholera toxin and of the toxin lt, their preparation and their use for the preparation of vaccines. |
TW082100298A TW239146B (it) | 1991-12-31 | 1993-01-18 | |
SA93130462A SA93130462B1 (ar) | 1991-12-31 | 1993-04-14 | طوافر mutants مزالة السمية مولدة للمناعة من سم الكوليرا ومن سم غير ثابت حراريا , تحضيرها واستحدامها لتحضير اللقاحات |
US08/823,120 US6149919A (en) | 1991-12-31 | 1997-03-25 | Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines |
GR990400555T GR3029556T3 (en) | 1991-12-31 | 1999-03-04 | Immunogenic detoxified mutants of cholera toxin and of the toxin lt, their preparation and their use for the preparation of vaccines. |
US09/819,917 US20020044939A1 (en) | 1991-12-31 | 2001-03-28 | Immunogenic detoxified mutants of cholera toxin |
JP2002119970A JP3408529B2 (ja) | 1991-12-31 | 2002-04-22 | コレラトキシンの免疫原性無毒化変異体およびトキシンltの免疫原性無毒化変異体、それらの調製、ならびにワクチンの調製のためのそれらの使用 |
US10/986,582 US7872114B2 (en) | 1991-12-31 | 2004-11-12 | Immunogenic detoxified mutants of cholera toxin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI913513A IT1253009B (it) | 1991-12-31 | 1991-12-31 | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
Publications (3)
Publication Number | Publication Date |
---|---|
ITMI913513A0 ITMI913513A0 (it) | 1991-12-31 |
ITMI913513A1 ITMI913513A1 (it) | 1993-07-01 |
IT1253009B true IT1253009B (it) | 1995-07-10 |
Family
ID=11361457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ITMI913513A IT1253009B (it) | 1991-12-31 | 1991-12-31 | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
Country Status (18)
Country | Link |
---|---|
US (1) | US6149919A (it) |
EP (3) | EP0620850B1 (it) |
JP (2) | JP3394774B2 (it) |
AT (3) | ATE277183T1 (it) |
AU (1) | AU3347693A (it) |
CA (1) | CA2127091C (it) |
DE (3) | DE69233417T2 (it) |
DK (3) | DK0620850T3 (it) |
ES (3) | ES2277195T3 (it) |
GR (1) | GR3029556T3 (it) |
IT (1) | IT1253009B (it) |
MX (1) | MX9207685A (it) |
MY (1) | MY108154A (it) |
PT (1) | PT1484404E (it) |
SA (1) | SA93130462B1 (it) |
SG (2) | SG48217A1 (it) |
TW (1) | TW239146B (it) |
WO (1) | WO1993013202A1 (it) |
Families Citing this family (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9513371D0 (en) * | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
ATE275970T1 (de) | 1993-10-05 | 2004-10-15 | Celltech Pharmaceuticals Ltd | Impfstoffzusammensetzungen |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
US5981730A (en) * | 1994-04-13 | 1999-11-09 | The General Hospital Corporation | RPS gene family, primers, probes, and detection methods |
US6436407B1 (en) | 1994-08-26 | 2002-08-20 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic adjuvant |
US6019982A (en) * | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
GB9603314D0 (en) * | 1996-02-16 | 1996-04-17 | Biocine Spa | Immunogenic detoxified mutant toxins |
GB9622660D0 (en) * | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
WO1998023763A1 (en) * | 1996-11-29 | 1998-06-04 | The General Hospital Corporation | Heterologous antigens in live cell v. cholerae strains |
AU6044598A (en) * | 1997-01-29 | 1998-08-18 | The Administrators Of The Tulane Eductional Fund | Mutant enterotoxin effective as a non-toxic adjuvant for hiv |
EP1486215A3 (en) * | 1997-03-21 | 2006-04-12 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
EP0887403A3 (en) * | 1997-06-27 | 2000-12-06 | Chiron S.P.A. | Attenuated Vibrio cholerae strains |
WO1999010372A1 (en) | 1997-08-27 | 1999-03-04 | Chiron Corporation | Molecular mimetics of meningococcal b epitopes |
AU3089599A (en) * | 1998-03-18 | 1999-10-11 | Smithkline Beecham Corporation | Production of purified mutant enterotoxin for use as an adjuvant |
US6033673A (en) * | 1998-03-18 | 2000-03-07 | The Administrators Of Tulane Educational Fund | Double mutant enterotoxin for use as an adjuvant |
US6576244B1 (en) | 1998-06-19 | 2003-06-10 | Acambis, Inc. | LT and CT in parenteral immunization methods against helicobacter infection |
DE19851282A1 (de) * | 1998-11-06 | 2000-05-11 | Schweiz Serum & Impfinst | Zusammensetzung einer pharmazeutisch wirksamen Substanz, appliziert in einem spezifischen Delivery-System zur Prävention und Behandlung von Infektions-Krankheiten |
EP1175144A4 (en) * | 1998-12-22 | 2002-10-30 | Thompson Boyce Plant Res | ORAL ADMINISTRATION IMMUNOGENIC BACTERIAL ENTEROTOXINS EXPRESSED IN TRANSGENIC PLANTS |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
WO2000039302A2 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
CA2689696C (en) | 1999-02-26 | 2013-08-06 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
JP2002537355A (ja) | 1999-02-26 | 2002-11-05 | カイロン コーポレイション | 抗原の粘膜送達のための生体接着剤およびアジュバントの使用 |
US7115730B1 (en) | 1999-04-27 | 2006-10-03 | Chiron Srl | Immunogenic detoxified mutant E. coli LT-A-toxin |
GB9919468D0 (en) | 1999-08-17 | 1999-10-20 | Smithkline Beecham Biolog | Vaccine |
WO2001019998A1 (en) * | 1999-09-15 | 2001-03-22 | Mogam Biotechnology Research Institute | Novel detoxified mutants of escherichia coli heat-labile enterotoxin |
US7186560B2 (en) * | 1999-09-21 | 2007-03-06 | Rutgers, The State University Of New Jersey | High level expression of immunogenic proteins in the plastids of higher plants |
CA2385484A1 (en) * | 1999-09-21 | 2001-03-29 | Rutgers, The State University Of New Jersey | Site-specific recombination system to manipulate the plastid genome of higher plants |
GB9923060D0 (en) | 1999-09-29 | 1999-12-01 | Chiron Spa | Vaccine |
US7384640B1 (en) | 1999-09-30 | 2008-06-10 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant |
JP5072159B2 (ja) | 1999-10-26 | 2012-11-14 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 粘膜アジュバントとしての植物レクチン |
WO2001070257A1 (en) * | 2000-03-17 | 2001-09-27 | Uab Research Foundation | Chimeric nontoxic mutants of enterotoxins as mucosal adjuvants for cell-mediated or humoral immunity |
WO2001089456A2 (en) * | 2000-05-19 | 2001-11-29 | The Administrators Of The Tulane Educational Fund | Hybrid lt-a/ct-b holotoxin for use as an adjuvant |
WO2002046477A2 (en) | 2000-12-07 | 2002-06-13 | Chiron Corporation | Endogenous retroviruses up-regulated in prostate cancer |
EP1363663B1 (en) | 2001-01-12 | 2011-03-02 | Novartis Vaccines and Diagnostics, Inc. | Nucleic acid mucosal immunization |
EP2316482A1 (en) | 2001-03-19 | 2011-05-04 | Intercell USA, Inc. | Transcutaneous immunostimulation |
US7534936B2 (en) * | 2001-03-29 | 2009-05-19 | Rutgers, The State University Of New Jersey | Transgenic plants having transformed plastid genomes and progeny thereof |
DK2292802T3 (en) | 2001-05-22 | 2015-03-09 | Us Gov Health & Human Serv | Development of mutations useful for attenuation of dengue viruses and chimeric dengue viruses |
IL159209A0 (en) | 2001-06-07 | 2004-06-01 | Wyeth Corp | Mutant forms of cholera holotoxin as an adjuvant |
AU2002346249B2 (en) * | 2001-06-07 | 2007-03-15 | The Regents Of The University Of Colorado | Mutant Forms of Cholera Holotoxin as an Adjuvant |
US8481043B2 (en) | 2001-06-22 | 2013-07-09 | Cpex Pharmaceuticals, Inc. | Nasal immunization |
WO2003004657A1 (en) | 2001-07-05 | 2003-01-16 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
EP2412242A3 (en) | 2001-07-05 | 2012-06-13 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
ES2615362T3 (es) | 2001-07-27 | 2017-06-06 | Glaxosmithkline Biologicals Sa | Adhesinas de meningococos |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
EP2572707A3 (en) | 2002-02-20 | 2013-11-06 | Novartis Vaccines and Diagnostics, Inc. | Microparticles with adsorbed polypeptide-containing molecules |
JP2005532789A (ja) | 2002-03-15 | 2005-11-04 | ワイス・ホールデイングス・コーポレーシヨン | 減少した酵素活性を有する型別不能なインフルエンザ菌(Haemophilusinfluenza)のP4タンパク質の変異体 |
EP1532161B1 (en) | 2002-06-13 | 2012-02-15 | Novartis Vaccines and Diagnostics, Inc. | Vectors for expression of hml-2 polypeptides |
JP2005539039A (ja) * | 2002-08-27 | 2005-12-22 | ダウ アグロサイエンシィズ エルエルシー | 鳥類及び家禽類におけるアジュバントとしてのエシェリシア・コリ熱不安定性毒素の使用 |
US20080159957A1 (en) | 2002-10-01 | 2008-07-03 | W Michael Kavanaugh | Anti-Cancer and Anti-Infectious Disease Compositions and Methods for Using Same |
DK2395073T3 (en) | 2002-11-01 | 2017-10-23 | Glaxosmithkline Biologicals Sa | Process for drying. |
WO2004043286A2 (en) * | 2002-11-14 | 2004-05-27 | Pfizer Products Inc. | Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen |
WO2004060396A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Immunogenic compositions containing phospholpid |
US6743002B1 (en) * | 2003-02-03 | 2004-06-01 | Eaton Corporation | Rotary fluid pressure device and improved integral brake assembly |
US20040171565A1 (en) * | 2003-02-14 | 2004-09-02 | David Hone | DNA vaccines that expresses mutant ADP-ribosyltransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity |
EP1606386A4 (en) * | 2003-03-03 | 2007-07-18 | Univ Rutgers | REMOVAL OF PLASTIC SEQUENCES THROUGH TRANSIENT EXPRESSED LOCATION-SPECIFIC RECOMBINATION |
WO2004083251A2 (en) * | 2003-03-17 | 2004-09-30 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
GB0308198D0 (en) * | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
WO2005020964A1 (en) | 2003-06-02 | 2005-03-10 | Chiron Corporation | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
GB0313242D0 (en) * | 2003-06-09 | 2003-07-16 | Imp College Innovations Ltd | Pulmonary immunopathology |
PL1660123T3 (pl) | 2003-09-02 | 2013-08-30 | Glaxosmithkline Biologicals Sa | Szczepionka rotawirusowa |
US20100015211A1 (en) | 2004-11-01 | 2010-01-21 | Barnett Susan W | Combination Approaches For Generating Immune Responses |
GB0503337D0 (en) | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
KR20150061019A (ko) | 2005-04-08 | 2015-06-03 | 와이어쓰 엘엘씨 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
JP2009511636A (ja) | 2005-10-18 | 2009-03-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | アルファウイルスレプリコン粒子による粘膜免疫および全身免疫 |
US8143474B2 (en) * | 2006-04-18 | 2012-03-27 | Rutgers, The State University Of New Jersey | Compositions and methods for increasing transgene expression in the plastids of higher plants |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
WO2008094188A2 (en) | 2006-07-17 | 2008-08-07 | Anza Therapeutics, Inc. | Methods and compositions using listeria for enhancing immunogenicity by prime boost |
JP2010530895A (ja) * | 2007-06-21 | 2010-09-16 | アンジェリカ セラピューティックス,インク. | 修飾毒素 |
EP2244695A1 (en) | 2007-12-07 | 2010-11-03 | Novartis AG | Compositions for inducing immune responses |
WO2009110944A1 (en) * | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Modified toxins |
US9415006B2 (en) | 2008-05-23 | 2016-08-16 | The Regents Of The University Of Michigan | Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same |
WO2009155484A2 (en) | 2008-06-20 | 2009-12-23 | Wyeth | Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains |
US20100092526A1 (en) | 2008-09-26 | 2010-04-15 | Nanobio Corporation | Nanoemulsion therapeutic compositions and methods of using the same |
US9023363B2 (en) * | 2008-10-21 | 2015-05-05 | International Vaccine Institute | A1 moiety of cholera toxin A subunit as an adjuvant for mucosal and systemic vaccines |
BRPI1005670A8 (pt) | 2009-01-05 | 2017-12-26 | Epitogenesis Inc | composições adjuvantes e processos de uso. |
EP2405758B1 (en) | 2009-03-09 | 2016-04-27 | Molecular Express, Inc. | Methods and compositions for liposomal formulation of antigens and uses thereof |
ES2566646T3 (es) | 2009-06-16 | 2016-04-14 | The Regents Of The University Of Michigan | Vacunas en nanoemulsión |
SG10201406432RA (en) | 2009-06-22 | 2014-11-27 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
BRPI1015567A2 (pt) | 2009-06-22 | 2021-08-31 | Wyeth Llc | Composições imunogênicas de antígenos de staphylococcus aureus |
AR077636A1 (es) | 2009-07-08 | 2011-09-14 | Abbott Biologicals Bv | Vacuna viral y uso de la misma |
US8241608B2 (en) | 2010-03-23 | 2012-08-14 | Development Center For Biotechnology | Treating allergy with detoxified E. coli heat-labile enterotoxin |
ES2613630T3 (es) | 2010-05-23 | 2017-05-25 | Aduro Biotech, Inc. | Métodos y composiciones que utilizan Listeria para un tratamiento auxiliar del cáncer |
HUE048398T2 (hu) | 2010-06-04 | 2020-07-28 | Wyeth Llc | Vakcinakészítmények |
US8658603B2 (en) | 2010-06-16 | 2014-02-25 | The Regents Of The University Of Michigan | Compositions and methods for inducing an immune response |
HUE052850T2 (hu) | 2010-08-23 | 2021-05-28 | Wyeth Llc | Neisseria meningitidis RLP2086 antigéneket tartalmazó stabil készítmények |
NZ607224A (en) | 2010-09-10 | 2014-11-28 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
DK2654784T3 (en) | 2010-12-22 | 2017-02-13 | Wyeth Llc | STABLE IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENES |
US20140287022A1 (en) | 2011-04-26 | 2014-09-25 | Molecular Express, Inc. | Liposomal formulations |
CN103717235A (zh) | 2011-06-24 | 2014-04-09 | 埃皮托吉尼西斯有限公司 | 作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物 |
MX2014005548A (es) | 2011-11-14 | 2014-08-21 | Novartis Ag | Complejos inmunogenicos de carbomeros polianionicos y polipeptidos env y metodos de manufactura y usos de los mismos. |
KR101763625B1 (ko) | 2012-03-09 | 2017-08-01 | 화이자 인코포레이티드 | 수막염균 조성물 및 이의 사용 방법 |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
EP3608401A1 (en) | 2012-07-05 | 2020-02-12 | Ohio State Innovation Foundation | Compositions and methods related to viral vaccines |
WO2014044690A1 (en) | 2012-09-18 | 2014-03-27 | Valneva Austria Gmbh | Improved vaccines |
DK2912186T3 (da) | 2012-10-24 | 2021-02-22 | Platelet Targeted Therapeutics Llc | Behandling rettet mod blodplader |
CA2943263C (en) | 2012-12-20 | 2018-12-04 | Pfizer Inc. | Glycoconjugation process |
CN105188747A (zh) | 2013-02-01 | 2015-12-23 | 葛兰素史密斯克莱生物公司 | 包含toll样受体激动剂的免疫组合物的皮内递送 |
ES2685894T3 (es) | 2013-03-08 | 2018-10-15 | Pfizer Inc. | Polipéptidos de fusión inmunogénicos |
CA2902905A1 (en) | 2013-03-15 | 2014-09-25 | Claude Geoffrey Davis | Modified toxins |
RU2662968C2 (ru) | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Иммуногенная композиция против neisseria meningitidis (варианты) |
EP3063171B1 (en) | 2013-11-01 | 2019-07-24 | University Of Oslo | Albumin variants and uses thereof |
US9993541B2 (en) | 2013-11-13 | 2018-06-12 | University Of Oslo | Outer membrane vesicles and uses thereof |
WO2015071763A2 (en) | 2013-11-15 | 2015-05-21 | Oslo Universitetssykehus Hf | Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof |
WO2016130569A1 (en) | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
WO2015138455A1 (en) | 2014-03-11 | 2015-09-17 | Regents Of The University Of Minnesota | Porcine epidemic diarrhea virus vaccines and methods of use thereof |
US11083788B2 (en) | 2014-10-10 | 2021-08-10 | The Regents Of The University Of Michigan | Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease |
EP3270959A1 (en) | 2015-02-19 | 2018-01-24 | Pfizer Inc | Neisseria meningitidis compositions and methods thereof |
WO2016141320A2 (en) | 2015-03-05 | 2016-09-09 | Northwestern University | Non-neuroinvasive viruses and uses thereof |
WO2016179034A2 (en) | 2015-05-01 | 2016-11-10 | The Trustees Of The University Of Pennsylvania | Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs |
PE20180172A1 (es) | 2015-05-04 | 2018-01-22 | Pfizer | Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos |
CN108348593B (zh) | 2015-08-31 | 2022-08-16 | 泰克诺瓦克斯股份有限公司 | 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗 |
WO2017062246A1 (en) | 2015-10-05 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human rota virus g9p[6] strain and use as a vaccine |
WO2017158421A1 (en) | 2016-03-14 | 2017-09-21 | University Of Oslo | Anti-viral engineered immunoglobulins |
WO2017158426A1 (en) | 2016-03-14 | 2017-09-21 | University Of Oslo | Engineered immunoglobulins with altered fcrn binding |
WO2017201390A1 (en) | 2016-05-19 | 2017-11-23 | The Regents Of The University Of Michigan | Novel adjuvant compositions |
WO2017210215A1 (en) | 2016-05-31 | 2017-12-07 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Zika virus vaccine and methods of production |
EP3471761A2 (en) | 2016-06-21 | 2019-04-24 | University Of Oslo | Hla binding vaccine moieties and uses thereof |
GB201614799D0 (en) | 2016-09-01 | 2016-10-19 | Glaxosmithkline Biologicals Sa | Compositions |
US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
WO2018096396A1 (en) | 2016-11-22 | 2018-05-31 | University Of Oslo | Albumin variants and uses thereof |
SG11201906519RA (en) | 2017-01-31 | 2019-08-27 | Pfizer | Neisseria meningitidis compositions and methods thereof |
WO2018183666A1 (en) | 2017-03-31 | 2018-10-04 | Boston Medical Center Corporation | Methods and compositions using highly converved pneumococcal surface proteins |
JP2020533338A (ja) | 2017-09-07 | 2020-11-19 | ユニバーシティ オブ オスロUniversity of Oslo | ワクチン分子 |
WO2019048936A1 (en) | 2017-09-07 | 2019-03-14 | University Of Oslo | VACCINE MOLECULES |
AU2021211012A1 (en) | 2020-01-24 | 2022-08-25 | Aim Immunotech Inc. | Methods, compositions, and vaccines for treating a virus infection |
US20230146256A1 (en) | 2020-04-17 | 2023-05-11 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF |
US20230321212A1 (en) | 2020-08-26 | 2023-10-12 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
EP4313132A1 (en) | 2021-03-31 | 2024-02-07 | Vib Vzw | Vaccine compositions for trypanosomatids |
CN113788893B (zh) * | 2021-08-11 | 2022-08-09 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 一种快速富集霍乱弧菌的偶联特异性单克隆抗体的免疫磁珠及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666837A (en) * | 1982-05-24 | 1987-05-19 | Smithkline-Rit | DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits |
US4935364A (en) * | 1983-03-04 | 1990-06-19 | Swiss Serum And Vaccine Institute Berne | Method of isolating restriction fragment deletions in vibrio cholerae and products thereof |
GB8333131D0 (en) * | 1983-12-12 | 1984-01-18 | Glaxo Group Ltd | Microbiological process |
IL101715A (en) * | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
-
1991
- 1991-12-31 IT ITMI913513A patent/IT1253009B/it active IP Right Grant
-
1992
- 1992-12-30 DK DK93902138T patent/DK0620850T3/da active
- 1992-12-30 AT AT98200534T patent/ATE277183T1/de active
- 1992-12-30 DE DE69233417T patent/DE69233417T2/de not_active Expired - Lifetime
- 1992-12-30 WO PCT/EP1992/003016 patent/WO1993013202A1/en active IP Right Grant
- 1992-12-30 EP EP93902138A patent/EP0620850B1/en not_active Expired - Lifetime
- 1992-12-30 AT AT04076971T patent/ATE346932T1/de active
- 1992-12-30 DE DE69233667T patent/DE69233667T2/de not_active Expired - Lifetime
- 1992-12-30 SG SG1996008033A patent/SG48217A1/en unknown
- 1992-12-30 PT PT04076971T patent/PT1484404E/pt unknown
- 1992-12-30 ES ES04076971T patent/ES2277195T3/es not_active Expired - Lifetime
- 1992-12-30 EP EP98200534A patent/EP0869181B1/en not_active Expired - Lifetime
- 1992-12-30 EP EP04076971A patent/EP1484404B1/en not_active Expired - Lifetime
- 1992-12-30 DK DK04076971T patent/DK1484404T3/da active
- 1992-12-30 ES ES93902138T patent/ES2127808T3/es not_active Expired - Lifetime
- 1992-12-30 ES ES98200534T patent/ES2227762T3/es not_active Expired - Lifetime
- 1992-12-30 DK DK98200534T patent/DK0869181T3/da active
- 1992-12-30 SG SG9901947A patent/SG93200A1/en unknown
- 1992-12-30 AU AU33476/93A patent/AU3347693A/en not_active Abandoned
- 1992-12-30 AT AT93902138T patent/ATE177145T1/de active
- 1992-12-30 JP JP51144793A patent/JP3394774B2/ja not_active Expired - Lifetime
- 1992-12-30 DE DE69228563T patent/DE69228563T2/de not_active Expired - Lifetime
- 1992-12-30 CA CA002127091A patent/CA2127091C/en not_active Expired - Lifetime
- 1992-12-31 MY MYPI92002409A patent/MY108154A/en unknown
- 1992-12-31 MX MX9207685A patent/MX9207685A/es unknown
-
1993
- 1993-01-18 TW TW082100298A patent/TW239146B/zh active
- 1993-04-14 SA SA93130462A patent/SA93130462B1/ar unknown
-
1997
- 1997-03-25 US US08/823,120 patent/US6149919A/en not_active Expired - Lifetime
-
1999
- 1999-03-04 GR GR990400555T patent/GR3029556T3/el unknown
-
2002
- 2002-04-22 JP JP2002119970A patent/JP3408529B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IT1253009B (it) | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini | |
US6419932B1 (en) | Antigen of hybrid M protein and carrier for Group A streptococccal vaccine | |
ES2139879T3 (es) | Adyuvante de la mucosa no toxico. | |
AU585481B2 (en) | Non-toxinogenic vibrio cholerae mutants | |
GB9622660D0 (en) | Immunogenic detoxified mutant toxin | |
CA2131729A1 (en) | Helicobacter pylori proteins useful for vaccines and diagnostics | |
CA2022420A1 (en) | Escherichia coli vaccine | |
ES2039773T3 (es) | Procedimiento para preparar una preparacion farmaceutica para el tratamiento de la diabetes mellitus. | |
NO914541L (no) | Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner | |
FI101632B1 (fi) | Menetelmä Bordetella pertussis-toksiinin alayksikön analogien valmistamiseksi ja niitä koodaavia rekombinantti-DNA-molekyylejä | |
DE69032408T2 (de) | Kreuzschützende salmonella impfstoffe | |
GR3030834T3 (en) | Herpes simplex virus vp16 vaccines | |
TW275632B (it) | ||
DE68911461T2 (de) | Derivate des basischen Mensch-/Rinder-Fibroblastwachstumsfaktors. | |
FI102544B1 (fi) | Menetelmä E.coli-kannan valmistamiseksi | |
BR9807927A (pt) | Uso de uma leishmania mutante na preparação de uma vacina, formulação de vacina, processo de vacinação contra leishmania, uso de uma leishmania mutante na preparacão de uma vacina para a profilaxia e/ou o tratamento de leishmaniose, e, formulação farmacêutica | |
周祖华 et al. | Clinical and experimental observations on treatment of peptic ulcer with wei yang an (easing peptic-ulcer) capsule | |
Tabaraie et al. | Evaluation of immunoprophylactic activities of purified porins of Salmonella typhi 0-901 and Salmonella typhimurium Ra-30 | |
Magni et al. | In vivo efficacy of cefcanel daloxate in comparison with cefaclor | |
Chen et al. | Construction of a bivalent candidate vaccine strain against ETEC and Salmonella disease | |
ES2145691A1 (es) | Nuevo gen de mucor circinelloides, plasmido que lo contiene y su utilizacion en la produccion de carotenoides. | |
RU2001132095A (ru) | Штамм бактерий Escherichia coli N 27 0138 К88, используемый для изготовления вакцин и диагностических препаратов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
0001 | Granted | ||
TA | Fee payment date (situation as of event date), data collected since 19931001 |
Effective date: 19971223 |